Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Manhattan Scientifics's cash to debt ratio for the quarter that ended in Jun. 2024 was 0.63.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Manhattan Scientificscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.
The historical rank and industry rank for Manhattan Scientifics's Cash-to-Debt or its related term are showing as below:
MHTX's Cash-to-Debt is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.635 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Manhattan Scientifics Cash-to-Debt Related Terms
Manhattan Scientifics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Manhattan Scientifics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MHTX vs TBIO, CUTRQ, EMED: Cash-to-Debt Comparison
For the Medical Devices subindustry, Manhattan Scientifics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Manhattan Scientifics Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Manhattan Scientifics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Manhattan Scientifics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Manhattan Scientifics (MHTX) has a Cash-to-Debt of 0.63 as of Jun. 2024.
Is Manhattan Scientifics' Cash-to-Debt too high?
Manhattan Scientifics' current Cash-to-Debt is 0.63. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Manhattan Scientifics' value of 0.63 is 61.5% below this industry median.
How does Manhattan Scientifics' Cash-to-Debt compare to TBIO and CUTRQ?
Manhattan Scientifics' Cash-to-Debt of 0.63 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash-to-Debt is 1.64. Manhattan Scientifics' value of 0.63 is 61.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Manhattan Scientifics's current Cash-to-Debt of 0.63 is 61.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Manhattan Scientifics's current Cash-to-Debt is 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Manhattan Scientifics stock overvalued right now?
Manhattan Scientifics (MHTX) has a current Cash-to-Debt of 0.63. The current Cash-to-Debt is 0.63 and 61.5% below the Medical Devices & Instruments industry median of 1.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Manhattan Scientifics (MHTX), the current Cash-to-Debt is 0.63 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. Its current focus is on the development of nanomaterials through the acquisition of Metallicum.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MHTX has been successfully added to your 
